Illumina Receives $1.2 Million Grant from the
2004-08-11 20:31 (New York)
National Institutes of Health to Continue Research on Bead-Based Proteomic
Arrays
SAN DIEGO--(BUSINESS WIRE)--Aug. 11, 2004--Illumina, Inc. (Nasdaq:ILMN)
announced today that it has been awarded a $1.2 million Phase 2 SBIR grant from
the National Institute of Allergy and Infectious Diseases, part of the National
Institutes of Health (NIH), for continued development of high-multiplex,
low-cost arrays to profile protein activity in small volumes of cells or
biological fluids.
Identification of protein profiles will be highly valuable in a broad range
of markets including research, clinical trials, and diagnostics. By profiling
and understanding protein activity, pharmaceutical and biotech firms can
identify more targeted drug compounds and discover relevant biomarkers for use
in diagnostic products. High-complexity protein arrays could be used to help
unravel the molecular basis of disease and certain genetic disorders.
According to Jay Flatley, Illumina President and CEO, "We're very pleased
that NIH recognizes the value of our BeadArray-based approach for proteomics
and has elected to fund additional research. If successful, this research may
lead to development of a third application area to complement the success of
Illumina technology in high throughput SNP genotyping and gene expression."
Illumina (www.illumina.com ) is developing next-generation tools for the
large-scale analysis of genetic variation and function. The Company's
proprietary BeadArray technology -- now used in leading genomics centers around
the world -- provides the throughput, cost effectiveness and flexibility
necessary to enable researchers in the life sciences and pharmaceutical
industries to perform the billions of tests necessary to extract medically
valuable information from advances in genomics and proteomics. This information
will help pave the way to personalized medicine by correlating genetic
variation and gene function with particular disease states, enhancing drug
discovery, allowing diseases to be detected earlier and more specifically, and
permitting better choices of drugs for individual patients. |
